DRUG (Bright Minds Biosciences) YoY EPS Growth: 68.39% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DRUG Bright Minds Biosciences Inc DRUG
34 GF Score
Price $65.16
! 1 Warning Sign
View Full Analysis

What is Bright Minds Biosciences YoY EPS Growth?

Bright Minds Biosciences DRUG -4.19% 34 YoY EPS Growth is 68.39% as of Jun. 2026. GuruFocus rates DRUG with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Bright Minds Biosciences's YoY EPS Growth for the quarter that ended in Jun. 2026 was 68.39%.

Bright Minds Biosciences's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was $-0.17.

Bright Minds Biosciences YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Bright Minds Biosciences's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bright Minds Biosciences YoY EPS Growth Chart

Bright Minds Biosciences Annual Data
Trend Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
YoY EPS Growth
Get a 7-Day Free Trial -1,239.44 -19.43 67.80 67.19 -168.13

Bright Minds Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,602.78 -235.20 -10,142.86 -170.99 68.39
DRUG
34GF Score
Bright Minds Biosciences Inc DRUG
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bright Minds Biosciences YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Bright Minds Biosciences's YoY EPS Growth for the fiscal year that ended in Sep. 2025 is calculated as:

YoY EPS Growth (A: Sep. 2025 )
=(Earnings per Share (Diluted) (A: Sep. 2025 )-Earnings per Share (Diluted) (A: Sep. 2024 ))/ | Earnings per Share (Diluted) (A: Sep. 2024 ) |
=(-1.287--0.48)/ | -0.48 |
=-168.13 %

Bright Minds Biosciences's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(-0.171--0.541)/ | -0.541 |
=68.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 68.39% mean?
Bright Minds Biosciences (DRUG) has a YoY EPS Growth of 68.39% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Bright Minds Biosciences and its competitors.
Is Bright Minds Biosciences' YoY EPS Growth too high?
Bright Minds Biosciences' current YoY EPS Growth is 68.39%. Overall, Bright Minds Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Bright Minds Biosciences' YoY EPS Growth compare to VRTX and REGN?
Bright Minds Biosciences' YoY EPS Growth of 68.39% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Bright Minds Biosciences and its competitors. Bright Minds Biosciences's current YoY EPS Growth is 68.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bright Minds Biosciences stock overvalued right now?
Bright Minds Biosciences (DRUG) has a current YoY EPS Growth of 68.39%. The current YoY EPS Growth is 68.39%. Bright Minds Biosciences' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Bright Minds Biosciences (DRUG), the current YoY EPS Growth is 68.39% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bright Minds Biosciences Business Description

Other Exchanges DRUG:Canada
Address 19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
34GF Score

Get the complete analysis for DRUG

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$65.16
Price